Cite
HARVARD Citation
Tarhini, A. et al. (2017). Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma. Melanoma research. 27 (4), p. . [Online].